licensing

News

Novartis has signed its second multibillion-dollar licensing deal with molecular glue degrader specialist Monte Rosa in less than a year.

News

Servier has pushed its emerging neurology pipeline into the clinical trials stage by licensing a drug for Fragile X syndrome from the UK's Kaerus.

News

Novartis is paying $160m upfront to activate an expanded R&D alliance with China's Argo Biopharma covering multiple cardiovascular disease drugs.

News

UK biotech OMass has revealed its first major pharma partnership, with Roche paying $20m upfront for an inflammatory bowel disease programme.

News

Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer, via an alliance with San Diego biotech Kumquat.

News

Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.